Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07557706 · ClinicalTrials.gov registry record · Phase 1
Using taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07557706 is a Phase 1 study that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 24 participants.
The verdict
NCT07557706, a Phase 1 study, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether a type of gentle nerve stimulation, called transcutaneous auricular Vagus Nerve Stimulation (taVNS), can help improve how the body regulates heart rate and blood pressure in people with Parkinson's Disease (PD). Problems with heart rate and blood pressure control are common and can make it harder for people to exercise or do daily activities. By using this non-invasive form of nerve stimulation and testing how it affects the body's natural responses, this study hopes to learn if taVNS could be a helpful tool to support physical therapy and improve overall function.
Interventions
- DEVICE transcutaneous auricular vagus nerve stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-09-15 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07557706
The ClinicalTrials.gov registry entry for NCT07557706 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which transcutaneous auricular vagus nerve stimulation is the first listed.
NCT07557706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07557706 about?
NCT07557706 is a clinical study titled "Using taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease". The purpose of this study is to find out whether a type of gentle nerve stimulation, called transcutaneous auricular Vagus Nerve Stimulation (taVNS), can help improve how the body regulates heart rate and blood pressure in people with Parkinson's Disease (PD). Problems with heart rate and blood pres...
What is the current status of trial NCT07557706?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-09-15. Estimated completion is 2026-12-31.
What interventions are being tested in trial NCT07557706?
The interventions under investigation include: transcutaneous auricular vagus nerve stimulation (DEVICE).
Who is sponsoring clinical trial NCT07557706?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.